Specific behaviour ‐ agitation · terminally ill adults with delirium
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Efficacy: response (categorical) BMRS change ≥ 50% from baseline to end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: response (continuous) YMRS/MRS change at the end of the study · acute mania
1 finding from 1 review
Efficacy: remission (categorical) YMRS ≤ 12/absence of DSM‐IV mania by end of study · acute mania
Lithium showed no clear difference in efficacy: remission (categorical) YMRS ≤ 12/absence of DSM‐IV mania… compared with risperidone (low certainty).
1 finding from 1 review
Acceptability: total withdrawals · acute mania
Lithium probably leads to higher acceptability: total withdrawals compared with risperidone (moderate certainty).
1 finding from 1 review
Drowsiness/somnolence (Event rate during treatment, length of treatment varied across trials) · acute mania
Lithium probably leads to lower adverse events: drowsiness/ somnolence compared with risperidone (moderate certainty).
1 finding from 1 review
Response rate at 8 weeks (primary efficacy outcome) · Children and adolescents with acute mania
Valproate may leads to lower response rate at 8 weeks (primary efficacy outcome) compared with risperidone (low certainty).
1 finding from 1 review
Number of participants with any adverse event (primary tolerability outcome) · Children and adolescents with acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: 1. Sedation · Children and adolescents with acute mania
It is very uncertain whether valproate changes adverse events ‐ Sedation At 8 weeks (secondary tolerability outcome) compared with risperidone (very low certainty).
1 finding from 1 review
Change in symptom severity at 5 ‐ 12 weeks (secondary efficacy outcome) · Children and adolescents with acute mania
1 finding from 1 review
Dropout · Children and adolescents with acute mania
Valproate showed no clear difference in dropout rate ‐ All‐cause (secondary acceptability outcome) At 5 ‐ 12… compared with risperidone (low certainty).
1 finding from 1 review
Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Adverse effects: Clinically important general adverse effect ‐ short term (EPSEs requiring medication) · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect ‐ short… compared with risperidone (very low certainty).
1 finding from 1 review
Death: Suicide and natural causes (no data) · schizophrenia
1 finding from 1 review
Length of hospital stay · schizophrenia
1 finding from 1 review
Mental state · schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason, short and medium term) compared with risperidone (very low certainty).
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Tranquillisation or asleep ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found